Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Biology of Bone Metastases in Patients With mCRPC

September 19th 2016

Conor Lynch, PhD, an associate professor of Tumor Biology at Moffitt Cancer Center, discusses the biology of bone metastases in patients with castration-resistant prostate cancer.

Study Addresses Appropriate Clinical Use of PSA Trial Data in Prostate Cancer

September 19th 2016

A treatment recommendation based on reduced prostate-specific antigen failure observed from early results of randomized controlled trials is not likely to prolong survival in men with moderate-to-severe comorbidities.

Dr. Luke Nordquist on the Impact of Additional Doses of Radium-223 in mCRPC

September 17th 2016

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a prospective study looking at the impact of an additional 6 doses of radium-223 dichloride in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.

Dr. Liauw on RT Advancements in Prostate Cancer

September 15th 2016

Stanley Liauw, MD, associate professor at the University of Chicago Medicine, discusses the advancements in radiation therapy (RT) over the last several years, and how he has seen the treatment affect his patients.

Exploring the "Dark Matter" in Prostate Cancer Genomics

September 14th 2016

Mark A. Rubin, MD, is an expert in prostate cancer genomics and pathology who has led key discoveries in the distinction between indolent and aggressive types of the malignancy.

Genomic Differences in Prostate Cancer Stages Are Coming Into Focus

September 13th 2016

Prostate cancer is slow-growing and readily curable in many cases, but the propensity for some tumors to develop into an aggressive, metastatic form that becomes resistant to androgen-targeting therapies continues to present a significant obstacle.

Expert Urges Revisiting PSA Screening After Pivotal Trial Update

September 13th 2016

After updated findings from the landmark Prostate, Lung, Colorectal, and Ovary screening trial were presented earlier this year, members of the oncology community strongly suggested that the United States Preventative Services Task Force revise its views on prostate-specific antigen screening for patients with prostate cancer.

Effects of Testosterone-Lowering Drugs in Patients With Prostate Cancer

September 13th 2016

Heather S. Jim, PhD, associate member in the Health Outcomes and Behavioral Department, Moffitt Cancer Center, discusses the effects of testosterone-lowering drugs used as a treatment for patients with prostate cancer.

Dr. Dreicer on Resistance to Antiandrogen Therapy in Prostate Cancer

September 8th 2016

Robert Dreicer, MD, Division of Hematology/Oncology, Department of Medicine, University of Virginia Health System, discusses resistance to antiandrogen therapy in prostate cancer.

Dr. Levine on Evolving Treatment Options for Patients With mCRPC

September 5th 2016

Richard M. Levine, MD, medical director, Moffitt International Plaza, Moffitt Cancer Center, discusses the available agents and their benefits for patients with metastatic castration-resistant prostate cancer.

Dr. Johnstone on Immediate Salvage Therapy for Prostate Cancer

September 2nd 2016

Peter A. Johnstone, MD, vice chair, Department of Radiation Oncology, Moffitt Cancer Center, discusses immediate salvage therapy for patients with prostate cancer and the most common physician questions surrounding the treatment.

Levine Lends Advice on Treating Patients With mCRPC

August 26th 2016

Richard Levine, MD, discusses the selection of therapies available for patients with metastatic castration-resistant prostate cancer and the next steps in the field.

Researcher Explores Biologic Basis for Disparities in Prostate Cancer Outcomes

August 26th 2016

Kosj Yamoah, MD, discusses health disparities in prostate cancer and unanswered questions researchers still need to tackle.

Accurate Risk Status Assessment Critical to Prostate Cancer Care

August 25th 2016

Julio Pow-Sang, MD, discusses the significance of assessing risk status, options for patients with prostate cancer whose risk status falls in a "grey-zone," and how technology is helping oncologists more accurately characterize risk.

Expert Discusses Novel Therapies, Biomarkers in mCRPC

August 25th 2016

Jingsong Zhang, MD, PhD, discusses his vision for treating patients with metastatic castration-resistant prostate cancer.

Understanding the Rationale for Bone-Targeted Therapy in mCRPC

August 23rd 2016

Conor Lynch, PhD, sheds light on the biology of bone metastases as well as the mechanism of action for bone-directed therapies for patients with metastatic castration-resistant prostate cancer.

Pfizer Oncology Reach Expanding With Medivation Acquisition

August 22nd 2016

Pfizer has announced plans to acquire the biopharmaceutical company Medivation, which is the developer of the androgen receptor inhibitor enzalutamide (Xtandi).

Psychological Effects From ADT a Growing Challenge in Prostate Cancer

August 22nd 2016

Heather Jim, MD, describes the psychological impacts of testosterone-lowering drugs for patients with prostate cancer—and what oncologists should do to help.

Expert Offers Insight on Postoperative Radiation in Prostate Cancer

August 19th 2016

Peter Johnstone, MD, provides insight on post-prostatectomy radiation therapy for patients with prostate cancer.

Second-Line Therapies for mCRPC Complicated by Drug Interactions and Dosing Issues

August 18th 2016

Approximately 4 years after the FDA approval of 2 powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis raised issues complicating treatment with the 2 drugs, as well as what oncologists do not yet know.